Weyerhaeuser Company (0LWG.L)
USD 28.68
(-2.85%)
USD 28.68
(-2.85%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 1.43 Billion | 2.83 Billion | 3.15 Billion | 1.52 Billion | 966 Million | 1.11 Billion |
| Net Income | 839 Million | 1.88 Billion | 2.6 Billion | 797 Million | -76 Million | 748 Million |
| Depreciation & Amortization | 500 Million | 480 Million | 577 Million | 757 Million | 1.2 Billion | 904 Million |
| Deferred income taxes | -6 Million | -30 Million | 14 Million | -56 Million | -169 Million | 72 Million |
| Stock-based compensation | 36 Million | 33 Million | 30 Million | 30 Million | 30 Million | 42 Million |
| Change in working capital | -13 Million | -112 Million | 53 Million | -122 Million | 66 Million | -227 Million |
| Other non-cash items | 77 Million | 581 Million | -122 Million | 123 Million | -91 Million | -427 Million |
| Investing Cash Flow | -508 Million | -759 Million | -325 Million | 185 Million | 187 Million | -440 Million |
| Investments in PPE | -680 Million | -763 Million | -590 Million | -706 Million | -384 Million | -427 Million |
| Acquisitions | - | - | - | 101 Million | 297 Million | - |
| Investment purchases | -664 Million | - | - | -888 Million | -550 Million | - |
| Sales/Maturities of investments | 830 Million | - | 261 Million | 888 Million | 550 Million | - |
| Other Investing Activities | 6 Million | 4 Million | 4 Million | 790 Million | 274 Million | -13 Million |
| Financing Cash Flow | -1.34 Billion | -2.49 Billion | -1.33 Billion | -1.35 Billion | -1.34 Billion | -1.16 Billion |
| Debt repayment | -14 Million | -1.2 Billion | -375 Million | -2.27 Billion | -2.1 Billion | -271 Million |
| Dividends payments | -1.21 Billion | -1.61 Billion | -884 Million | -381 Million | -1.01 Billion | -995 Million |
| Common Stock Repurchased | -131 Million | -543 Million | -100 Million | -33 Million | -60 Million | -366 Million |
| Common Stock Issuance | - | 16 Million | 51 Million | 33 Million | 1.84 Billion | 477 Million |
| Other Financing Activities | -9 Million | 856 Million | -22 Million | 1.29 Billion | -18 Million | -7 Million |
| Accounts receivables | 4 Million | 149 Million | -57 Million | -141 Million | 13 Million | 62 Million |
| Accounts payables | 35 Million | -111 Million | 113 Million | -17 Million | 43 Million | -172 Million |
| Inventory | -13 Million | -37 Million | -77 Million | -25 Million | -23 Million | -14 Million |
| Other working capital | -39 Million | -113 Million | 74 Million | 61 Million | 33 Million | -103 Million |
| Cash at beginning of period | 1.58 Billion | 1.99 Billion | 495 Million | 139 Million | 334 Million | 824 Million |
| Cash at end of period | 1.16 Billion | 1.58 Billion | 1.99 Billion | 495 Million | 139 Million | 334 Million |
| Capital Expenditure | -680 Million | -763 Million | -590 Million | -706 Million | -384 Million | -427 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -417 Million | -418 Million | 1.5 Billion | 356 Million | -195 Million | -490 Million |
| Free Cash Flow | 753 Million | 2.06 Billion | 2.56 Billion | 823 Million | 582 Million | 685 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 28 Million | 173 Million | 114 Million | 839 Million | 219 Million | 239 Million |
| Depreciation & Amortization | 125 Million | 126 Million | 125 Million | 500 Million | 126 Million | 122 Million |
| Deferred income taxes | - | - | - | -6 Million | -2 Million | -6 Million |
| Stock-based compensation | 10 Million | 12 Million | 10 Million | 36 Million | 10 Million | 9 Million |
| Change in working capital | 42 Million | 64 Million | -173 Million | -13 Million | -12 Million | 121 Million |
| Other non-cash items | 154 Million | 273 Million | 480 Million | 77 Million | -53 Million | 38 Million |
| Investing Cash Flow | -161 Million | -143 Million | -77 Million | -508 Million | 474 Million | -164 Million |
| Investments in PPE | -179 Million | -144 Million | -79 Million | -680 Million | -359 Million | -167 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | -39 Million | -53 Million | - | -664 Million | - | - |
| Sales/Maturities of investments | - | - | - | 830 Million | 830 Million | - |
| Other Investing Activities | -79 Million | 1 Million | 2 Million | 6 Million | 3 Million | 3 Million |
| Financing Cash Flow | -171 Million | -195 Million | -308 Million | -1.34 Billion | -771 Million | -281 Million |
| Debt repayment | - | - | - | -14 Million | -611 Million | -118 Million |
| Dividends payments | -145 Million | -146 Million | -248 Million | -1.21 Billion | -140 Million | -138 Million |
| Common Stock Repurchased | -27 Million | -49 Million | -50 Million | -131 Million | -22 Million | -24 Million |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 1 Million | -195 Million | -10 Million | -9 Million | 2 Million | -1 Million |
| Accounts receivables | 23 Million | -4 Million | -53 Million | 4 Million | 81 Million | 28 Million |
| Accounts payables | 13 Million | 37 Million | -51 Million | 35 Million | -8 Million | 60 Million |
| Inventory | 22 Million | 15 Million | -68 Million | -13 Million | -36 Million | 9 Million |
| Other working capital | -3 Million | 16 Million | -1 Million | -39 Million | -49 Million | 24 Million |
| Cash at beginning of period | 997 Million | 871 Million | 1.16 Billion | 1.58 Billion | 1.17 Billion | 1.09 Billion |
| Cash at end of period | 899 Million | 997 Million | 871 Million | 1.16 Billion | 1.16 Billion | 1.17 Billion |
| Capital Expenditure | -179 Million | -144 Million | -79 Million | -680 Million | -359 Million | -167 Million |
| Effect of forex changes on cash | - | - | - | - | - | 199 Million |
| Net cash flow / Change in cash | -98 Million | 126 Million | -293 Million | -417 Million | -9 Million | 78 Million |
| Free Cash Flow | 55 Million | 288 Million | 45 Million | 753 Million | -71 Million | 356 Million |
THBRF
0HEJ
0LD4
300777
EMR
0QPD